Table 1 Baseline characteristics of the patients*
CharacteristicPlacebo plus methotrexate (n = 186)Rituximab plus methotrexate (n = 277)
Gender (female/male), n (%)149 (80)/37 (20)225 (81)/52 (19)
Age (mean, years)53.052.5
Disease duration (mean, years)11.612.0
Swollen joint count (mean)23.223.2
Tender joint count (mean)33.233.2
RF positive (%)8080
CRP (mean, mg/dl)3.63.7
ESR (mean, mm/h)46.547.7
DAS28 (mean)6.86.8
HAQ-DI score (mean)1.91.8
No. of previous DMARDs† (mean)2.82.9
No. of previous TNF inhibitors (mean)1.51.5
Total Genant-modified Sharp score (mean)46.246.2
  • *Patients with radiographic data available at 56 weeks. †In addition to concurrent methotrexate.

  • CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; TNF, tumour necrosis factor.